Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population

Journal of Clinical Oncology

Volumn 33, Issue 26, 2015, Pages 2901-2907

  Song, Honglin ^a   Dicks, Ed ^a   Ramus, Susan J ^f   Tyrer, Jonathan P ^a   Intermaggio, Maria P ^f   Hayward, Jane ^c   Edlund, Christopher K ^f   Conti, David ^f   Harrington, Patricia ^a   Fraser, Lindsay ^c   Philpott, Susan ^c   Anderson, Christopher ^c   Rosenthal, Adam ^c   Gentry Maharaj, Aleksandra ^c   Bowtell, David D ^d,g,h   Alsop, Kathryn ^g   Cicek, Mine S ⁱ   Cunningham, Julie M ⁱ   Fridley, Brooke L ^j   Alsop, Jennifer ^a   Jimenez Linan, Mercedes ^b   Høgdall, Estrid ^k,l   Høgdall, Claus K ^m   Jensen, Allan ^k   Kjaer, Susanne Krüger ^k,m   Lubiński, Jan ⁿ   Huzarski, Tomasz ⁿ   Jakubowska, Anna ⁿ   Gronwald, Jacek ⁿ   Poblete, Samantha ^o   Lele, Shashi ^o   Sucheston Campbell, Lara ^o   Moysich, Kirsten B ^o   Odunsi, Kunle ^o   Goode, Ellen L ⁱ   Menon, Usha ^c   Jacobs, Ian J ^c,e   Gayther, Simon A ^f   Pharoah, Paul D P ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^k DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m Rigshospitalet   (Denmark)

ⁿ POMERANIAN MEDICAL UNIVERSITY   (Poland)

^o ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; DNA BINDING PROTEIN; RAD51B PROTEIN, HUMAN; RAD51C PROTEIN, HUMAN; RAD51D PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DNA STRAND BREAKAGE; FAMILY HISTORY; FEMALE; GENE; GENE SEQUENCE; GERMLINE MUTATION; HISTOPATHOLOGY; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY CONTROL; RAD51B GENE; RAD51C GENE; RAD51D GENE; AGED; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84952641660     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.2408     Document Type: Article

References (45)

1. Jervis S, Song H, Lee A, et al: Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J Med Genet 51:108-113, 2014
2. Stratton JF, Pharoah P, Smith SK, et al: A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105:493-499, 1998
3. Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer: Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78-85, 2000
4. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995
5. Gayther SA, Harrington P, Russell P, et al: Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis: UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet 58:451-456, 1996
6. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
7. Antoniou AC, Cunningham AP, Peto J, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: Updates and extensions. Br J Cancer 98:1457-1466, 2008
8. Song H, Cicek MS, Dicks E, et al: The contribution of deleterious germline mutations in BRCA1, BRCA2, and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet 23:4703-4709, 2014
9. Bolton KL, Tyrer J, Song H, et al: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42:880-884, 2010
10. Shen H, Fridley BL, Song H, et al: Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 4:1628, 2013
11. Song H, Ramus SJ, Tyrer J, et al: A genomewide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996-1000, 2009
12. Bojesen SE, Pooley KA, Johnatty SE, et al: Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45:371-384, 384e1-2, 2013
13. Goode EL, Chenevix-Trench G, Song H, et al: A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42:874-879, 2010
14. Permuth-Wey J, Lawrenson K, Shen HC, et al: Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 4:1627, 2013
15. Pharoah PD, Tsai YY, Ramus SJ, et al: GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 45:362-370, 370e1-e2, 2013
16. Chen K, Ma H, Li L, et al: Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. Nat Commun 5:4682, 2014
17. Couch FJ, Wang X, McGuffog L, et al: Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 9:e1003212, 2013
18. Antoniou AC, Easton DF: Risk prediction models for familial breast cancer. Future Oncol 2:257-274, 2006
19. Meindl A, Hellebrand H, Wiek C, et al: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42:410-414, 2010
20. Loveday C, Turnbull C, Ramsay E, et al: Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43:879-882, 2011
21. Rafnar T, Gudbjartsson DF, Sulem P, et al: Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 43:1104-1107, 2011
22. Rosenthal AN, Fraser L, Manchanda R, et al: Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 31:49-57, 2013
23. Li H, Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26:589-595, 2010
24. McKenna A, Hanna M, Banks E, et al: The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297-1303, 2010
25. Wang K, Li M, Hakonarson H: ANNOVAR: Functional annotation of genetic variants from highthroughput sequencing data. Nucleic Acids Res 38: e164, 2010
26. Adzhubei IA, Schmidt S, Peshkin L, et al: A method and server for predicting damaging missense mutations. Nat Methods 7:248-249, 2010
27. Sim NL, Kumar P, Hu J, et al: SIFT web server: Predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 40:W452-W457, 2012
28. Choi Y, Sims GE, Murphy S, et al: Predicting the functional effect of amino acid substitutions and indels. PLoS One 7:e46688, 2012
29. Eng L, Coutinho G, Nahas S, et al: Nonclassical splicing mutations in the coding and noncoding regions of the ATM gene: Maximum entropy estimates of splice junction strengths. Hum Mutat 23:67-76, 2004
30. Osorio A, Endt D, Fernandez F, et al: Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet 21:2889-2898, 2012
31. Soegaard M, Kjaer SK, Cox M, et al: BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 14: 3761-3767, 2008
32. Cancer Registrations in England. Office for National Statistics. http://www.ons.gov.uk/ons/rel/ vsob1/cancer-registrations-in-england/index.html
33. Tyrer JP, Guo Q, Easton DF, et al: The admixture maximum likelihood test to test for association between rare variants and disease phenotypes. BMC Bioinformatics 14:177, 2013
34. Loveday C, Turnbull C, Ruark E, et al: Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 44:475-476, 2012; author reply 476
35. Pelttari LM, Heikkinen T, Thompson D, et al: RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20:3278-3288, 2011
36. Pennington KP, Walsh T, Harrell MI, et al: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764-775, 2014
37. Thompson ER, Boyle SE, Johnson J, et al: Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat 33:95-99, 2012
38. Vuorela M, Pylkas K, Hartikainen JM, et al: Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat 130:1003-1010, 2011
39. Walsh T, Casadei S, Lee MK, et al: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108:18032-18037, 2011
40. Thompson ER, Rowley SM, Sawyer S, et al: Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. PLoS One 8:e54772, 2013
41. Wickramanayake A, Bernier G, Pennil C, et al: Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecol Oncol 127: 552-555, 2012
42. Lakhani SR, Manek S, Penault-Llorca F, et al: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10:2473-2481, 2004
43. Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410-419, 2001
44. Thompson D, Easton D, Breast Cancer Linkage Consortium: Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329-336, 2002
45. Miller KA, Sawicka D, Barsky D, et al: Domain mapping of the Rad51 paralog protein complexes. Nucleic Acids Res 32:169-178, 2004